NOBIVAC® DHPPi
For the active immunisation of dogs against canine distemper, infectious canine hepatitis, canine parvo virus disease and canine parainfluenza virus infection.
FOR ANIMAL USE ONLY
Nobivac® DHPPi
Reg. No. G2377 (Act 36/1947)
Namibia Reg. No. V97/24.1/900 NS2
Lyophilisate and solvent for suspension for injection
Only for use by or under the supervision of persons registered in terms of, or authorised in terms of, Section 23 (1) (c) of the Veterinary and Para-Veterinary Professions Act, 1982 (Act 19 of 1982).
INDICATIONS
For the active immunisation of dogs against canine distemper, infectious canine hepatitis, canine parvovirus disease and canine parainfluenza virus infection.
COMPOSITION
Each 0,5 mℓ vial of the lyophilised pellet contains live, attenuated strains of:
- canine distemper virus (CDV) not less than 104 TCID50
- canine adenovirus type 2 (CAV2) not less than 104 TCID50
- canine parvovirus (CPV) not less than 107 TCID50
- canine parainfluenza virus (CPI) not less than 105,5 TCID50
Each vial contains a single dose for reconstitution.
STORAGE INSTRUCTIONS
- Store between 2 °C and 8 °C in a refrigerator.
- Do not freeze.
- Protect from light.
- Avoid prolonged or repetitive exposure to high ambient temperatures.
- Allow the vaccine to gradually reach room temperature (20 °C to 25 °C) prior to use.
- After reconstitution, the vaccine must be administered within 30 minutes.
WARNINGS
- Only healthy dogs and puppies should be vaccinated.
- Pregnant animals may be vaccinated, if they have been vaccinated before with a vaccine against canine distemper, infectious canine hepatitis, canine parvo virus disease and canine parainfluenza virus.
- After the initial vaccination course has been completed, contact with potential sources of canine distemper virus, canine adenovirus and/or canine parvovirus infection should be avoided for at least 7 days, and for canine Parainfluenza virus for at least 4 weeks.
- Experience has shown that maternal parvovirus antibody status of the puppies in a litter varies greatly, and reliance should not be placed on serological examination of the bitch alone.
- Accidental self-injection may lead to a severe allergic reaction. Seek medical advice immediately and show this package leaflet to the physician.
- Do not store partially used containers for future use and use the entire contents once opened.
- KEEP OUT OF REACH OF CHILDREN, UNINFORMED PERSONS AND ANIMALS.
- Although this vaccine has been extensively tested under a large variety of conditions, failure thereof may ensue as a result of a wide range of reasons. If this is suspected, seek veterinary advice and notify the registration holder.
PRECAUTIONS
- Observe aseptic precautions. Ensure that all vaccination equipment (containers, syringes and needles) is clean and sterile prior to and during use. Use sterile equipment when administering the vaccine.
- Avoid contamination of the vaccine with traces of disinfectant and spirits.
- Avoid intravenous injection.
- As with all vaccines, hypersensitivity or anaphylactic reactions may occur.
- It is good vaccination practice when handling the vaccine to avoid contact with the eyes, hands and clothing.
- Destroy any unused vaccine and dispose of all the empty vaccine containers and disposable equipment after use in accordance with National Environmental Management: Waste Act, 2008 (Act No. 59 of 2008).
- Do not contaminate rivers, dams or any water sources with containers or waste.
DIRECTIONS FOR USE – USE ONLY AS DIRECTED
Vaccination Programme
The following recommendations are included since it is likely that immunisation with Nobivac® DHPPi will form part of a more comprehensive vaccination programme.
Primary course
A single injection should establish active immunity to canine distemper, infectious canine hepatitis and disease caused by canine parvovirus infection in dogs of 10 weeks of age or older.
Where earlier protection is required, a 1st dose may be given to puppies from 6 weeks of age, but because maternally derived passive antibody can interfere with the response to vaccination, a final dose at 10 weeks of age or older is generally recommended.
For an optimal response to the parainfluenza component, dogs should be vaccinated twice, 2 – 4 weeks apart with the final vaccination at 10 weeks of age or more.
If the initial primary course dose of Nobivac® DHPPi is delayed to 10 weeks of age or older, a single dose of Nobivac® DHPPi at 12 weeks of age or older should suffice to establish immunity for this component.
Revaccination
It is recommended that dogs be revaccinated against:
- Canine distemper, canine hepatitis, canine parvovirus infection – every 3 years.
- Canine parainfluenza virus infection – every year.
- Rabies – every 3 years (it may be modified to comply with local regulations).
DOSAGE AND ADMINISTRATION
The contents of 1 vial of reconstituted vaccine should be injected subcutaneously.
Reconstitute the Nobivac® DHPPi immediately prior to use, by adding the contents of 1 vial (1 mℓ) of any of the following: Nobivac® L6 (G4482), Nobivac® Rabies* (G2207), Nobivac® RL* (G2199) or Nobivac® Diluent.
* Nobivac® Rabies (G2207) and Nobivac® RL (G2199) is only to be used from 12 weeks of age.
PRESENTATION
Hydrolytical Type I glass vial, that contains an off-white or cream-coloured freeze-dried pellet, closed with a halogenated butyl rubber stopper and sealed with a coded aluminium cap.
Vials are packed in in polyethylene terephthalate (PET) trays or in cardboard boxes containing 10 or 50 single dose vials.
REGISTRATION HOLDER
Intervet South Africa (Pty) Ltd.
20 Spartan Road, Spartan
1619, RSA
Tel: +27 (0) 11 923 9300
E-mail: msdahza@msd.com
www.msd-animal-health.co.za
DATE OF PUBLICATION OF THIS PACKAGE INSERT 24 October 2024
| Zimbabwe Reg. No. E97/80.23.15/9470 Veterinary Classification: 802315 Distribution Category: PP |